Author

Aaron C. Logan

University of California, San FranciscoORCID 0000-0002-1179-5879Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:imaging· 1 Organism:mouse· 1 Research Focus:perturbation response prediction· 1

Frequent Co-Authors

Amrik S. KangiD· 2 shared Arun P. WiitaiD· 2 shared Corynn KasapiD· 2 shared Veronica SteriiD· 2 shared Abhilash BarpandaiD· 1 shared Adila IzgutdinaiD· 1 shared Andrew Koh· 1 shared Anil P. BidkariD· 1 shared

Activity by Year

2025-2025 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 32 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Amrik S. KangORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

ImmunologybioRxivPreprintSep 21, 2025

Bicistronic CAR T-cells Against CD70 & Active Integrin β2 Overcome Antigen Heterogeneity and Preserve Safety in Acute Myeloid Leukemia

Amrik S. Kang, H. A. Johnson, Nicole Lei…·Arun P. Wiita

This paper develops dual-antigen targeting CAR-T cells against CD70 and active integrin β2 to overcome AML antigen heterogeneity and reduce off-tumor toxicity.

DOI 10.1101/2025.09.21.677627

mouseexperimental assay

Cancer BiologybioRxivPreprintAug 21, 2025

Effective imaging and treatment of Acute Myeloid Leukemia with radiotheranostics targeting the activated conformation of integrin-Beta2

Anju Wadhwa, Haley E. Johnson, Kondapa Naidu Bobba…·Robert R. Flavell

This study demonstrates promising preclinical efficacy of aITGB2-targeted radiotheranostics for selective imaging and therapy in AML.

DOI 10.1101/2025.08.21.671206

humanimaging

Cancer BiologybioRxivPreprintJun 10, 2025

Multi-selective RAS(ON) Inhibition Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 and BCL2 Inhibitors in Acute Myeloid Leukemia

Bogdan Popescu, Matthew F. Jones, Madison Piao…·Catherine Choy Smith

This study evaluates RMC-7977, a RAS(ON) inhibitor, showing efficacy against RAS-driven resistance in AML and potential for combination therapies.

3 citations

humanexperimental assay